Sold as Xenon Xe 133, Xeneisol, Xenon Xe 133-V.S.S.. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 7 applications for Xenon Xe-133 (sold as Xenon Xe 133, Xeneisol, Xenon Xe 133-V.S.S.), first approved Oct 10, 1974, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Hyper Polarized Xenon-129 MRI vs Xenon-133 ScintigraphyChronic Obstructive Pulmonary Disease · University of Virginia | Phase 1 / Phase 2 | Recruiting | Nov 6, 2017 |
| Oct 10, 1974 | Xenon Xe 133NDA 17284 · New formulation or manufacturer | Shine | 11 | Marketed |
| Oct 11, 1974 | Xenon Xe 133NDA 17283 · New formulation or manufacturer | Lantheus Medcl | 0 | Discontinued |
| Mar 24, 1976 | Xenon Xe 133NDA 17550 · New formulation or manufacturer | Gen Electric | 3 | Discontinued |
| Nov 9, 1976 | Xenon Xe 133NDA 17256 · New formulation or manufacturer | Ge Healthcare | 4 | Discontinued |
| Nov 16, 1976 | Xenon Xe 133-V.S.S., Xenon Xe 133NDA 17687 · New formulation or manufacturer | Ge Healthcare | 3 | Discontinued |
| Mar 9, 1982 | Xenon Xe 133NDA 18327 · New formulation or manufacturer | Curium | 3 | Marketed |
| — | XeneisolNDA 17262 | Mallinckrodt | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Ge Healthcare
Mallinckrodt